The U.S. Food and Drug Administration (FDA) has cleared for market the NephroScan technetium-99m (Tc-99m) radiodiagnostic imaging agent from radiopharmaceuticals firm Theragnostics.
NephroScan detects kidney cortical defects in both adults and children. It is manufactured in Dresden, Germany, by ROTOP Pharmaka, and GE Healthcare will distribute the agent in the U.S., according to Theragnostics.
It is the company's first FDA-cleared drug, it said.
